A new therapeutic strategy for a common form of inherited blindness.

An international research team from the Institute for Ophthalmic Research at the University of Tübingen and the University of Padova has developed and tested a new therapeutic strategy for a common form of inherited retinal degeneration. Their results, published in the Journal of Controlled Release, show that combining targeted pharmacological inhibition with advanced nanoparticle drug delivery can significantly protect light sensitive retinal cells in experimental models.

Retinitis pigmentosa is a group of inherited eye disorders that progressively damage the retina and often lead to severe vision loss. A significant number of cases are caused by mutations in the rhodopsin gene, which is essential for vision in low light. One specific small genetic deletion, identified in patients from several countries, produces a misfolded rhodopsin protein. Instead of being correctly transported inside photoreceptor cells, the altered protein accumulates, stresses the cell, and contributes to its degeneration.

Cells normally rely on internal quality control systems to handle misfolded proteins. A central component of this system is a protein called VCP, valosin containing protein. Earlier experimental work indicated that partially reducing VCP activity can, under certain conditions, improve photoreceptor survival. Turning this concept into a practical therapy has been difficult because VCP inhibitor compounds are poorly soluble and hard to deliver efficiently to retinal tissue.

To address this problem, the researchers compared three different approaches in a mouse model carrying the same rhodopsin defect found in patients. They tested specificsmall molecule inhibitors for VCP alone, the same inhibitor packaged into biodegradable nanoparticles for controlled release, and gene silencing using short RNA molecules delivered with magnetic particles. The treatments were evaluated both in retinal tissue samples and after injections into the eye of mice, suffering of retinal degeneration.

All three approaches showed protective effects. The nanoparticle based system stood out because it enabled a slower, more sustained drug release and produced the strongest and longest lasting retinal protection. Treated photoreceptor cells showed improved rhodopsin localization and increased survival and the treated mice retained their eyesight significantly longer.

This study provides solid preclinical evidence that combining targeted molecular therapy with nanotechnology based delivery may open new avenues for treating certain genetic retinal diseases. Further research is needed to establish safety and effectiveness before translation to clinical use.

Original publication in Journal of Controlled Release: Ocular delivery of different valosin-containing protein (VCP) inhibitory formulations prevents retinal degeneration in rho∆I255 mice